Carol Ashe is a seasoned life sciences executive with over 25 years of experience in biotech, pharmaceutical and consumer healthcare business development, corporate development and venture capital including a wide and diverse range of transactional expertise spanning academic institutions, early stage start-ups, and pharmaceutical companies.
Carol is currently the Chief Business Officer at the New York Genome Center, an independent, nonprofit academic research institution focused on translating genomic research into the development of new therapies for human disease. In addition, Carol is also a non-executive Director for Aptose Biosciences, a clinical-stage oncology company. Previously, Carol served as Vice President of Corporate Development for Endo’s branded, generic and platform drug delivery pharmaceutical business units. Prior to that, Ms. Ashe was a partner at GlaxoSmithKline’s corporate venture capital fund, SR One. Earlier, Ms. Ashe was the head of GSK’s US Corporate Legal Group supporting US-based mergers, acquisitions, and equity investments and, prior to that, the head of GSK’s global Business Development Transactions Legal Team supporting both the pharmaceutical and consumer healthcare business units.
Ms. Ashe received her Bachelor of Science degree in Biology from Pennsylvania State University, her law degree from Villanova University School of Law and is a registered patent attorney.